Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A method of tracking immune cells to detect immune response. The method including steps of identifying a patient having a disease associated with an organ; administering biocompatible magnetic nanoparticles into the blood stream of the patient; and obtaining a magnetic resonance image of the organ. The presence of hyperintense or hypointense spots in the magnetic resonance image indicates immune response in the patient.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A method of treating a condition related to iron deficiency. The method includes steps of identifying a patient having a condition related to iron deficiency and administering an effective amount of biocompatible iron oxide nanoparticles to the patient. The biocompatible iron oxide nanoparticles each contains an iron oxide core that is covered by one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker linking, via a covalent bond, the polyethylene glycol group and the silane group.

Abstract: A method of treating a condition related to iron deficiency. The method includes steps of identifying a patient having a condition related to iron deficiency and administering an effective amount of biocompatible iron oxide nanoparticles to the patient. The biocompatible iron oxide nanoparticles each contains an iron oxide core that is covered by one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker linking, via a covalent bond, the polyethylene glycol group and the silane group.

Abstract: A method of tracking immune cells to detect immune response. The method including steps of identifying a patient having a disease associated with an organ; administering biocompatible magnetic nanoparticles into the blood stream of the patient; and obtaining a magnetic resonance image of the organ. The presence of hyperintense or hypointense spots in the magnetic resonance image indicates immune response in the patient.

Abstract: Disclosed is a pH-sensitive hyaluronic acid derivative, comprising at least one repeat unit as shown in the following formula (I), wherein HA represents a unit comprising N-acetyl-D-glucosamine and D-glucuronic acid, q represents an integer of 2 to 10,000; A represents a biocleavable linkage comprising at least one of hydrazone, acetal, ketal and imine; M represents at least one of a hydrophobic fragment, a hydrophilic fragment, and an amphiphilic fragment, and p represents the number of [A-M] directly grafted onto each HA unit, p represents an integer of 0 to 4, and the p of each HA unit is not 0 at the same time.

Abstract: A thermosensitive nanostructure for hyperthermia treatment. Magnetic nanoparticles are encapsulated in a thermosensitive polymer nanostructure having a lower critical solution temperature (LCST) of about 40-45° C. The thermosensitive polymer nanostructure may carry a drug. When the magnetic nanoparticles are heated to 40-45° C. by application of an alternating magnetic field in hyperthermia treatment, the thermosensitive polymer nanostructure collapses to release the drug, thus providing concurrent drug treatment.

Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is CH2CH2Ol, and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.

Abstract: The invention provides phosphors composed of Eu(1-x-w)MaxMbwMgMc10O17, wherein Ma is Yb, Sn, Ce, Tb, Dy, or combinations thereof, and 0<x<0.5, Mb is Ca, Sr, Ba, or combinations thereof, and 0?w?0.5, and Mc is Al, Ga, Sc, In, or combinations thereof. The blue phosphors emit blue light under the excitation of ultraviolet light or blue light, and the phosphors may be further collocated with different colored phosphors to provide a white light illumination device. The blue phosphors of the invention can efficiently utilize light in solar cells.

Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.

Abstract: Methotrexate-modified nanoparticles that target tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles.

Abstract: The invention provides phosphors composed of Eu(1-x-w)MaxMbwMgMc10O17, wherein Ma is Yb, Sn, Ce, Tb, Dy, or combinations thereof, and 0<x<0.5, Mb is Ca, Sr, Ba, or combinations thereof, and 0?w?0.5, and Mc is Al, Ga, Sc, In, or combinations thereof. The blue phosphors emit blue light under the excitation of ultraviolet light or blue light, and the phosphors may be further collocated with different colored phosphors to provide a white light illumination device. The blue phosphors of the invention can efficiently utilize light in solar cells.

Abstract: The invention provides a phosphor emitting UV and visible light, which may be collocated with other phosphors to provide a white light illumination device, composed of (M1-xREx)9M?(PO4)7 or M9(M?1-yRE?y)(PO4)7 , wherein M is Mg, Ca, Sr, Ba, Zn or combinations thereof, M? is Sc, Y, La, Gd, Al, Ga, In or combinations thereof, RE is Pr, Nd, Eu, Gd, Tb, Ce, Dy, Yb, Er, Sc, Mn, Zn or combinations thereof, RE? is Pr, Nd, Gd, Tb, Ce, Dy, Yb, Er, Bi or combinations thereof, 0.001?x?0.8, and 0.001?y<1.0.

Abstract: A cadmium tin oxide (Cd1?xSnxO) multi-layer laminate is disclosed. The laminate comprises: a substrate; and a layer of Cd1?xSnxO which is not an epitaxial structure; wherein, the composition of Sn/(Cd+Sn) is 1˜20%. The method for producing the Cd1?xSnxO multi-layer laminate is also described here. The method comprises steps of: (a) providing metal or oxide targets for sputtering films of Cd1?xSnxO; and (b) sputtering films of Cd1?xSnxO from the targets onto the substrate; wherein the composition of Sn/(Cd+Sn) is 1˜20%.

Abstract: The invention provides a red phosphor composed of M(Eu1-x-yLaxBiy)4Si3O13, wherein M is Ca, Sr, Ba, or combinations thereof, 0<x<1, and 0<y<1. Under excitation of blue light or ultraviolet light, the red phosphor emits red light having a major emission peak of about 613 nm. The red phosphor of the invention may be collocated with green and blue phosphors to provide a white light illumination device.